NEW YORK, NY / ACCESSWIRE / June 29, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Amazon.com, Inc. (NASDAQ:AMZN)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/amazon-com-inc-loss-submission-form?prid=29382&wire=1
Lead Plaintiff Deadline: July 5, 2022
Class Period: February 1, 2019 - April 5, 2022
Allegations against AMZN include that: (i) Amazon engaged in anticompetitive conduct in its private-label business practices, including giving Amazon products preference over those of its competitors and using third-party sellers' non-public data to compete with them; (ii) the foregoing exposed Amazon to a heightened risk of regulatory scrutiny and/or enforcement actions; (iii) Amazon's revenues derived from its private-label business were in part the product of impermissible conduct and thus unsustainable; and (iv) as a result, the defendants' public statements throughout the class period were materially false and/or misleading.
Oscar Health, Inc. (NYSE:OSCR)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/oscar-health-inc-loss-submission-form?prid=29382&wire=1
Lead Plaintiff Deadline: July 11, 2022
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Oscar Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's March 2021 initial public offering.
Allegations against OSCR include that: (1) Oscar was experiencing growing COVID-19 testing and treatment costs; (2) Oscar was experiencing growing net COVID costs; (3) Oscar would be negatively impacted by an unfavorable prior year Risk Adjustment Data Validation result relating to 2019 and 2020; (4) Oscar was on track to be negatively impacted by significant SEP membership growth; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Axsome Therapeutics, Inc. (NASDAQ:AXSM)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/axsome-therapeutics-inc-loss-submission-form?prid=29382&wire=1
Lead Plaintiff Deadline: July 12, 2022
Class Period: December 30, 2019 - April 22, 2022
Allegations against AXSM include that: (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07, the Company's medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application ("NDA") on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration ("FDA") reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong